Outcomes of Triple-Negative Versus Non-Triple-Negative Breast Cancers Managed with Breast-Conserving Therapy

  • Bhatti, Abu Bakar Hafeez (Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre) ;
  • Khan, Amina Iqbal (Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre) ;
  • Siddiqui, Neelam (Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre) ;
  • Muzaffar, Nargis (Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre) ;
  • Syed, Aamir Ali (Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre) ;
  • Shah, Mazhar Ali (Department of Radiation Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre) ;
  • Jamshed, Arif (Department of Radiation Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre)
  • Published : 2014.03.30


Background: Triple negative breast cancer is associated with aggressive behavior and high risk of local and regional failure. Aggressive surgical intervention is considered suitable. This makes role of breast conserving therapy (BCT) debatable in these patients. The objective of this study was to compare outcome of BCT for triple negative versus non-triple negative breast cancer. Materials and Methods: Medical records of patients who underwent breast conserving therapy from 1999 to 2009 at Shaukat Khanum Cancer Hospital and had complete receptor status information were extracted. Patients were divided into triple negative breast cancer (TNBC) and non-TNBC. Patient characteristics, medical treatment modalities and adverse events were compared. Expected five year locoregional recurrence free, disease free and overall survival was calculated. The Cox proportional hazard model was used to identify independent predictors of outcome. Results: A total of 194 patients with TNBC and 443 with non-TNBC were compared. Significant difference was present for age at presentation (p<0.0001), family history (p=0.005), grade (p<0.0001) and use of hormonal therapy (p<0.0001). The number of locoregional failures, distant failures and mortalities were not significantly different. No significant difference was present in 5 year locoregional recurrence free (96% vs 92%, p=0.3), disease free (75% vs 74%, p=0.7) and overall survival (78% vs 83%, p=0.2). On multivariate analysis, tumor size, nodal involvement and hormonal treatment were independent predictors of negative events. Conclusions: Breast conserving therapy has comparable outcomes for triple negative and non-triple negative breast cancers.


  1. Abdulkarim BS, Cuartero J, Hanson J, et al (2011). Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol, 29, 2852-8.
  2. Adami HO, Malker B, Holmberg L, et al (1986). The relation between survival and age at diagnosis in breast cancer. N Engl J Med, 315, 559-63.
  3. Adkins FC, Gonzalez-Angulo AM, Lei X, et al (2011). Triplenegative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol, 18, 3164-73.
  4. Bauer KR, Brown M, Cress RD, et al (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer, 109, 1721-8.
  5. Chu QD, Henderson AE, Ampil F, et al (2012). Outcome for patients with triple-negative breast cancer is not dependent on race/ethnicity. Int J Breast Cancer, 764570.
  6. Chung M, Chang HR, Bland KI, et al (1996). Younger women with breast carcinoma have a poorer prognosis than older women. Cancer, 77, 97-103.<97::AID-CNCR16>3.0.CO;2-3
  7. Dawood S, Broglio K, Kau SW, et al (2009). Triple receptornegative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol, 27, 220-6.
  8. Dent R, Trudeau M, Pritchard KI, et al (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13, 4429-34.
  9. Fisher B, Anderson S, Bryant J, et al (2002). Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med, 347, 1233-41.
  10. Freedman GM, Anderson PR, Li T, et al (2009). Locoregional recurrence of triple-negative breast cancer after breastconserving surgery and radiation. Cancer, 115, 946-51.
  11. Haffty BG, Yang Q, Reiss M, et al (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 24, 5652-7.
  12. Kwan ML, Kushi LH, Weltzien E, et al (2009). Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res, 11, 31.
  13. Lowery AJ, Kell MR, Glynn RW, et al (2012). Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat, 133, 831-41.
  14. Li CY, Zhang S, Zhang XB, et al (2013). Clinicopathological and prognostic characteristics of triple-negative breast cancer (TNBC) in Chinese patients: a retrospective study. Asian Pac J Cancer Prev, 14, 3779-84.
  15. Ma KK, Chau WW, Wong CHN, et al (2012). Triple negative status is a poor prognostic indicator in Chinese women with breast cancer: a ten year review. Asian Pac J Cancer Prev, 13, 2109-14.
  16. Mersin H, Yildirim E, Berberoglu U, et al (2008). The prognostic importance of triple negative breast carcinoma. Breast, 17, 341-6.
  17. Millar EK, Graham PH, O'Toole SA, et al (2009). Prediction of local recurrence, distant metastases, and death after breastconserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol, 28, 4701-8.
  18. Nguyen PL, Taghian AG, Katz MS, et al (2008). Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol, 26, 2373-8.
  19. Nielsen TO, Hsu FD, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74.
  20. O'Brien KM, Cole SR, Tse CK, et al (2010). Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res, 16, 6100-10.
  21. Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52.
  22. Rakha EA, Reis-Filho JS, Ellis IO (2008). Basal-like breast cancer: a critical review. J Clin Oncol, 26, 2568-81.
  23. Sharif MA, Mamoon N, Mushtaq S, et al (2010). Steroid hormone receptor association with prognostic markers in breast carcinoma in Northern Pakistan. J Coll Physicians Surg Pak, 20, 181-5.
  24. Sidoni A, Cavaliere A, Bellezza G, et al (2003). Breast cancer in young women: clinicopathological features and biological specificity. Breast, 12, 247-50.
  25. Solin LJ, Hwang WT, Vapiwala N(2009). Outcome after breast conservation treatment with radiation for women with triplenegative early-stage invasive breast carcinoma. Clin Breast Cancer, 9, 96-100.
  26. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74.
  27. Spitale A, Mazzola P, Soldini D, et al (2009). Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol, 20,628-35.
  28. Van Dongen JA, Voogd AC, Fentiman IS, et al (2000). Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst, 92, 1143-50.
  29. Voduc KD, Cheang MC, Tyldesley S, et al (2010). Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol, 28, 1684-91.
  30. Wang J, Xie X, Wang X, et al (2013). Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis. Surg Oncol, 22, 247-55.
  31. Zaky SS, Lund M, May KA, et al (2011). The negative effect of triple-negative breast cancer on outcome after breastconserving therapy. Ann Surg Oncol, 18, 2858-65.

Cited by

  1. Clinicopathology Figures and Long-term Effects of Tamoxifen Plus Radiation on Survival of Women with Invasive Ductal Carcinoma and Triple Negative Breast Cancer vol.16, pp.12, 2015,
  2. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients vol.16, pp.1, 2016,
  3. Breast parenchymal signal enhancement ratio at preoperative magnetic resonance imaging: association with early recurrence in triple-negative breast cancer patients vol.57, pp.7, 2016,
  4. Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide vol.11, pp.3, 2016,
  5. Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy vol.57, pp.5, 2016,